Followers | 611 |
Posts | 26763 |
Boards Moderated | 1 |
Alias Born | 08/12/2010 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, April 01, 2018 3:56:20 AM
Finalizing an FDA study in Phase IV we could be on the verge of an uptick that would blow away USR**M's move last year. Many reasons can apply here. One they are on the verge of validation of their patented technology in stem cells which creates HUGE INTELLECTUAL VALUE IN THEIR TECHNOLOGY AND COMPANY. Believe me much higher than a market cap of 600,000 or even 25 million(USR**M). We could be pushing 100's of million's in worth from a market cap perspective. Also if I was a bio-tech company looking to buy out a company and was flush with cash I would most definitely trigger a sell off with notes due to LOAD THE BOAT BIGTIME. The stock has been pushed down from a 52 week high over .50 cents and more recently a few months ago at .25 cents. Our 200dma is in the .18 range. The 52 week low is .0021. We are ground floor here IMHO.
The SS is incredible last checked in the 233 million O/S range. At most we are in the 400-450million O/S range.
Nothingness considering the revenue potential.
One thing we do know as seasoned investors VOLUME MEANS SOMETHING AND IN THIS CASE YOU CAN BET ITS GOOD!!!!
Definitely something to think about. I am not selling for pennies that's for sure!
We know larger Bio's and Pharma' are looking to add to their revenue streams and they are doing it via mergers/acquisitions.
Why 2018 Could Be An Explosive Year For Biotech Mergers
https://www.investors.com/news/technology/why-2018-could-be-an-explosive-year-for-biotech-mergers/
$11 billion biotech binge fuels forecasts of 2018 M&A surge
https://www.reuters.com/article/uk-biotech-m-a-analysis/11-billion-biotech-binge-fuels-forecasts-of-2018-ma-surge-idUSKBN1EX1KF
Why 2018 is a make-or-break year for pharma
Many drugmakers have neglected their pipelines, and will look to acquisitions to bolster them
https://www.marketwatch.com/story/why-2018-is-a-make-or-break-year-for-pharma-2017-12-19
Tax Overhaul Could Jolt Dollar as U.S. Companies Bring Home Cash
Corporations could repatriate as much as $400 billion in earnings and cash from abroad
https://www.wsj.com/articles/tax-overhaul-could-jolt-dollar-as-u-s-companies-bring-home-cash-1514206800
ALL POSTS are just my opinion! Never BUY/SELL stock based on only them! Perform your own DD and make your own decision!
Recent CELZ News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/05/2024 08:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:02:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:45:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • Business Wire • 03/27/2024 01:00:00 PM
- Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access • Business Wire • 03/07/2024 02:15:00 PM
- Biotech Finds Mid-Week Success Following FDA Announcement • AllPennyStocks.com • 03/06/2024 09:10:00 PM
- Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy • Business Wire • 03/06/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:05:37 PM
- Creative Medical Technology Holdings Provides Corporate Update • PR Newswire (US) • 11/15/2023 01:00:00 PM
- Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain • PR Newswire (US) • 10/10/2023 12:00:00 PM
- Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain • PR Newswire (US) • 09/19/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 08:45:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/29/2023 09:37:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/28/2023 01:00:18 PM
- Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements • PR Newswire (US) • 06/28/2023 12:00:00 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM